Company: CDT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010405
Chunk: 2

Company: CDT Equity Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
009  
     2,955 
  
    Operating loss 
     (4,009) 
     (2,955)
  
    Other income (expense): 

    Other income (expense), net 
     (969) 
     (487)
  
    Interest income 
     8  
     9 
  
    Interest expense 
     (176) 
     (119)
  
    Total other (expense) income, net 
     (1,137) 
     (597)
  
    Net loss 
    $(5,146) 
    $(3,552)
  
    Basic and diluted net loss per share 
    $(1.32) 
    $(4.81)
  
    Basic weighted-average common shares outstanding 
     3,885,758  
     738,295 
  
    Diluted weighted-average common shares outstanding 
     3,885,758  
     738,295 
  
    Comprehensive loss: 

    Foreign currency translation adjustment 
     (68) 
     (23)
  
    Total comprehensive loss 
    $(5,214) 
    $(3,575)

The
accompanying notes are an integral part of these condensed consolidated financial statements.

2

CONDUIT
PHARMACEUTICALS INC.

CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(unaudited)

(in
thousands, except share amounts)

    Shares  
    Amount  
    capital  
    deficit  
    income  
    deficit 

    Common stock  
    Additional paid-in  
    Accumulated  
    Accumulated other comprehensive  
    Total stockholders’ Equity 

    Shares  
    Amount  
    capital  
    deficit  
    income  
    (deficit) 

    Balance at January 1, 2025 
     1,384,801  
    $14  
    $21,880  
    $(29,101) 
    $414  
    $(6,793)
  
    Issuance of common stock for services 
     2,450,191  
     1  
     2,211  
     -  
     -  
     2,212 
  
    Issuance of common stock under the ATM program 
     4,345